Literature DB >> 1416646

Inhibition of nasopharyngeal colonization of Hemophilus influenzae by oral immunization.

Y Kurono1, K Shimamura, G Mogi.   

Abstract

Nontypeable Hemophilus influenzae organisms were inoculated into the nasopharynx of BALB/c mice immunized by oral administration of formalin-killed bacteria. Salivary antibodies and the colonization of H influenzae in the nasopharynx were investigated in order to clarify the effect of oral immunization. Salivary immunoglobulin A antibody titers against H influenzae were significantly increased by oral immunization, but salivary immunoglobulin G antibody titers were not. The bacteria inoculated into the nasopharynx were more rapidly eliminated in immunized mice than in control mice. The results suggest that oral immunization might be useful in preventing otitis media with effusion by inhibiting the colonization of the nasopharynx by pathogenic bacteria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416646     DOI: 10.1177/0003489492101s1004

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol Suppl        ISSN: 0096-8056


  4 in total

1.  The acylated form of protein D of Haemophilus influenzae is more immunogenic than the nonacylated form and elicits an adjuvant effect when it is used as a carrier conjugated to polyribosyl ribitol phosphate.

Authors:  M Akkoyunlu; A Melhus; C Capiau; O van Opstal; A Forsgren
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

Review 2.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 3.  Mouse models for human otitis media.

Authors:  Dennis R Trune; Qing Yin Zheng
Journal:  Brain Res       Date:  2009-03-06       Impact factor: 3.252

Review 4.  Mouse models as a tool to unravel the genetic basis for human otitis media.

Authors:  Qing Yin Zheng; Rachel Hardisty-Hughes; Steve D M Brown
Journal:  Brain Res       Date:  2006-05-26       Impact factor: 3.252

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.